MedTrace Logo

Menin-Inhibitor Targeted Maintenance in AML

NCT07563010 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-05-04

No results posted yet for this study

Summary

Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.

Conditions

  • Relapsed Adult AML
  • Stem Cell Transplant Complications
  • Acute Myeloid Leukemia
  • Transplant-Related Hematologic Malignancy

Interventions

DRUG

Revumenib

oral tablets

DRUG

Placebo

oral tablets

Sponsors & Collaborators

Principal Investigators

  • Steven Devine, M.D · NMDP

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-31
Primary Completion
2031-06-30
Completion
2031-06-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07563010 on ClinicalTrials.gov